Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aurinia starts Phase III AURORA trial of voclosporin for lupus nephritis

Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) began the Phase III AURORA trial evaluating Luveniq voclosporin (LX211) to treat lupus nephritis. The double-blind, international trial will enroll about 320 patients to receive twice-daily

Read the full 316 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers